New data boosts our confidence in Lilly's obesity pill. Plus, Google's new AI features

The 10-year Treasury yield rose to 4.665% and the 30-year hit 5.19%, its highest level in almost 19 years, as high energy prices and inflation fears pressured markets and favored defensive healthcare names. Eli Lilly gained over 2% after Citi said 74% of endocrinologists see Wegovy's fasting requirements affecting prescribing, supporting the case for Lilly's oral GLP-1 Foundayo, which Citi estimates could reach $2.8 billion in 2026 versus $1.5 billion consensus. Alphabet was down over 1% despite Google's I/O announcements, including Gemini 3.5 and new AI tools, as investor expectations were already high.

Analysis

Higher rates and firmer energy are not just a macro backdrop; they are a duration shock that changes relative positioning inside the market. The first-order winners are balance-sheet-light, defensive compounders and cash-generative retail names with less sensitivity to refinancing and discretionary demand, while the losers are businesses where valuation depends on long runway monetization or consumer elasticity. That helps explain why software upside faded intraday: in a 4.6%-plus 10-year world, investors are less willing to pay for distant ARR growth unless near-term FCF conversion is unmistakable.

The healthcare tape is more interesting than the usual “defensive rotation” explanation. The key second-order effect in oral GLP-1s is not just category expansion, but switching friction: if one product materially reduces regimen complexity, it can convert physician intent into share gains even when efficacy is slightly inferior. That creates a path for the simpler product to win the broader prescriber base over time, while the more cumbersome product is likely to over-index in specialty segments willing to tolerate administration constraints.

On the AI side, the market is increasingly treating product demos as table stakes rather than monetization catalysts. When usage metrics scale but the stock still sells off, that usually means expectations have moved from adoption to conversion: investors want evidence that engagement is turning into search defense, ad pricing, or incremental cloud demand. If that proof is absent over the next 1-2 quarters, AI beneficiaries with stretched multiples remain vulnerable to further de-rating even if product news flow stays strong.

Near term, the biggest reversal risk is a bond-market repricing in either direction: softer inflation or a de-escalation in energy would quickly unwind the defensive rotation and punish the most rate-sensitive short books. Conversely, if yields keep climbing into month-end, cyclicals tied to housing and consumer spending likely stay under pressure, while healthcare and high-quality defensives should continue to absorb incremental capital. The key is that this is a regime trade, not a one-day headline trade.

Key Decisions for Investors

• Long LLY vs short NVO for a 3-6 month horizon: the cleaner user experience should compound share gains as prescribers optimize for adherence and workflow simplicity; use pullbacks to build, and exit if oral share data shows no narrowing by next prescription-checkpoint.
• Avoid chasing GOOGL into strength on event day; use any post-event weakness as a staged entry only if management can quantify ad/search monetization lift within 1-2 quarters. Otherwise, expect multiple compression if product enthusiasm outpaces revenue translation.
• Short a software basket vs long healthcare defensives over the next 2-4 weeks if 10-year yields hold above 4.6%: rate pressure should keep duration-sensitive software underperforming while rate-insulated cash generators attract flows.
• Underweight HD and similar consumer-exposed retailers on any bounce until rates stabilize; higher mortgage/credit costs plus energy pressure can delay spending, making the risk/reward skew negative for 1-2 quarter earnings revisions.
• If bond yields start to roll over, cover defensive longs quickly and rotate into quality cyclicals/semis; the current defensive bid is fragile and could unwind sharply if inflation fear loses momentum.